Q2 2020 Editas Medicine Inc Earnings Call Transcript
Good afternoon, and welcome to Editas Medicine's Second Quarter 2020 Conference Call. (Operator Instructions) Please be advised that this call is being recorded at the company's request. I would now like to turn the call over to Mark Mullikin, Vice President of Finance and Investor Relations at Editas Medicine.
Thank you, operator. Good afternoon, everyone, and welcome to our second quarter 2020 conference call. Earlier this afternoon, we issued 2 press releases. The first press release announces the termination of our agreement with Allergan for the development of ocular medicines, returning full control of these programs to Editas Medicine. The second press release provides our financial results and corporate updates for the second quarter of 2020.
A replay of today's call will be available on the Investors section of our website approximately 2 hours after its completion. After our prepared remarks, we will open the call for Q&A.
As a reminder, various
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
